The FINANCIAL The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will follow 200 patients with cirrhosis – scarring caused by long-term damage of the liver – to uncover why some patients experience liver failure or develop liver cancer. Researchers from the Universities of Edinburgh and Newcastle hope their findings will lead to earlierThe FINANCIAL The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will follow 200 patients with cirrhosis – scarring caused by long-term damage of the liver – to uncover why some patients experience liver failure or develop liver cancer. Researchers from the Universities of Edinburgh and Newcastle hope their findings will lead to earlier » The FINANCIAL Health&Beauty
Edinburgh Innovations | £30M ADVANCE study paves the way for new… ed.ac.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ed.ac.uk Daily Mail and Mail on Sunday newspapers.
Newcastle University to lead £30m largest ever liver cirrhosis study chroniclelive.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chroniclelive.co.uk Daily Mail and Mail on Sunday newspapers.
The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical company, Boehringer Ingelheim.